ERBB3 and head and neck squamous cell carcinoma: These findings were also confirmed using a widely-used Pik3ca wild type syngeneic mouse HNSCC model, MOC1 cells32, which also responded to the HER3/anti-PD-1 combination: mice responded to anti-PD-1 but most responders regrew after treatment termination.